All In Biotech

Drug Trial Radar · NCT07379580

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Feb 20, 2026

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Coalition for Epidemic Preparedness Innovations
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.

Conditions

  • Mpox (Monkeypox)
  • Smallpox
  • Orthopoxvirus Infection

Interventions

  • BNT166aBiological

    Intramuscular injection. Injections should be given in the deltoid muscle, using the same non-dominant arm for all IMP doses.

  • PlaceboOther

    Intramuscular injection. Injections should be given in the deltoid muscle, using the same non-dominant arm for all IMP doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number (and percentage) of participants with at least one solicited local reaction (pain, erythema/redness, induration/swelling)Time frame: For up to 7 days following each dose
  2. Number (and percentage) of participants with at least one solicited systemic reaction (fever, headache, fatigue/tiredness, muscle pain/myalgia, joint pain/arthralgia, chills, diarrhea, vomiting)Time frame: For up to 7 days following each dose
  3. Number (and percentage) of participants with at least one use of antipyretics/analgesicsTime frame: For up to 7 days following each dose
  4. Number (and percentage) of participants with at least one unsolicited adverse event (AE) (post-Dose 1)Time frame: From Dose 1 to 28 days post-Dose 1
  5. Number (and percentage) of participants with at least one unsolicited AE (post-Dose 2)Time frame: From Dose 2 to 28 days post-Dose 2
  6. Number (and percentage) of participants with at least one serious adverse eventTime frame: From Dose 1 until the end of study, i.e., up to ~14 months
  7. Number (and percentage) of participants with at least one AE of special interestTime frame: From Dose 1 until the end of study, i.e., up to ~14 months
  8. Number (and percentage) of participants with at least one medically attended AETime frame: From Dose 1 until the end of study, i.e., up to ~14 months
  9. Number (and percentage) of participants with at least one AE leading to a participant's withdrawal from the studyTime frame: From Dose 1 until the end of study, i.e., up to ~14 months

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Kinshasa UNIKIN

    Kinshasa, Democratic Republic of the Congo · Recruiting

  • Institute National de Recherche Biomedicale

    Kinshasa, Democratic Republic of the Congo · Recruiting

  • TASK Applied Science

    Cape Town, South Africa · Recruiting

  • TREAD Research Pty Ltd

    Cape Town, South Africa · Recruiting

  • Desmond Tutu Health Foundation Masiphumelele Clinic

    Cape Town, South Africa · Recruiting

  • Perinatal HIV Research Unit

    Johannesburg, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.